Investing in TB Vaccines Is Urgent for India and the Asian Region: Dr. Soumya Swaminathan
Swaminathan
, Chairperson of the M.S. Swaminathan Research Foundation (MSSRF) and former Chief Scientist at the World Health Organization, has called for urgent and sustained investment in tuberculosis (TB) vaccines, particularly for
high-burden countries
like India.
Speaking at the first day of the World Health Summit (WHS) Regional Meeting during the panel discussion Asia Region TB Vaccine R&D Financing, Dr. Swaminathan emphasised that an effective TB vaccine could save millions of lives and generate significant economic benefits.
Referencing the World Health Organization's
TB vaccine investment
case, Dr. Swaminathan explained how a viable vaccine could avert deaths, reduce treatment needs, prevent catastrophic healthcare expenditure, and lead to measurable gains in GDP.
'It's a continuum—people get infected, some clear it, some develop active disease. But even subclinical TB carries a significant risk of mortality, and the outcomes worsen without early diagnosis or treatment,' she said.
Acknowledging India's contribution to TB vaccine research, Dr. Swaminathan noted that the overall TB vaccine pipeline remains stagnant, with several candidates stuck in early trial phases for over a decade.
'These candidates neither move forward nor drop off. What we need is decisive action—to either advance them or let them go,' she stated.
She pointed to M72, a promising candidate now in Phase 3 trials with support from the Bill & Melinda Gates Foundation and Wellcome Trust, as an example of the high costs and slow timelines that dominate vaccine development.
'It's a $500 million project. But we cannot afford to spend that amount on every candidate,' Dr. Swaminathan stated, adding that TB trials take years to reach endpoints. 'Then comes data analysis, regulatory submissions, and finally, scale-up. That's the traditional timeline.'
Drawing on her experience with the WHO Solidarity Trial during the COVID-19 pandemic, she explained how digital tools, international collaboration, and adaptive regulatory approaches had helped compress vaccine timelines.
'We had 35 to 40 countries participating, and everything was done online. The cost was negligible. That model can work for TB too,' she said.
Dr. Swaminathan also praised India's ability to execute large-scale adult vaccination campaigns, as demonstrated during COVID-19. She urged stakeholders to apply similar urgency and innovation in rolling out TB vaccines.
'COVID showed us that timelines can be compressed. I was involved in the Solidarity Trial. It spanned 35–40 countries, was fully digital, and the cost was negligible compared to traditional trials. Vaccine companies contributed doses, doctors volunteered their time, and forms were designed to be completed in minutes—even in busy ICUs. ICMR was involved in that too,' she said.
'Similarly, regulatory agencies came together during COVID. They didn't take years to assess dossiers. Benchmarks were set. WHO created target product profiles, and global regulators like the FDA and EMA aligned on efficacy and safety standards. Minimum safety data was accepted to proceed, with continued monitoring post-rollout. Manufacturers even scaled up production before final efficacy results were available—governments absorbed that risk,' Dr. Swaminathan added.
India launched the COVID Suraksha programme and invested significantly. So, it's possible to compress a 10–15-year vaccine development timeline into something much shorter—if the global community aligns.
'Of course, TB is not COVID. Endpoints take longer. But that doesn't mean we must accept the status quo. We don't have to wait decades for results.'
Highlighting the inefficiencies in the current system, she advocated for a global mechanism to evaluate and prioritise the most promising TB vaccine candidates. 'Right now, companies are very protective of their own candidates. We're not making the most efficient use of our limited resources.'
She concluded by urging policymakers,
global health agencies
, and vaccine developers to collaborate, invest, and rethink the way TB vaccines are developed and deployed. 'It's not just about science. It's about saving lives—and doing it faster.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Study finds COVID-19 may have aged blood vessels by 5 years, especially among women
New Delhi: A COVID-19 infection could age one's blood vessels by about five years, especially among women, according to a new study. The effect was found to be stronger among women who experienced persistent symptoms after recovering from COVID-19 -- collectively termed 'long Covid' -- such as shortness of breath and fatigue. "Since the pandemic, we have learned that many people who have had (COVID-19) are left with symptoms that can last for months or even years. However, we are still learning what's happening in the body to create these symptoms," lead researcher Rosa Maria Bruno from Universite Paris Cite, France, said. The study, published in the European Heart Journal, looked at around 2,400 people -- about half were women -- from across 16 countries, including Australia, Brazil and those in Europe. While blood vessels are known to become stiffer with age, a COVID-19 infection can accelerate the process and can heighten the risk of developing cardiovascular disease, including stroke and heart attack, the researchers said. The participants' vascular (blood vessel) age was measured using a device that looks at how quickly a wave of blood pressure travels between the carotid artery (in the neck) and femoral arteries (in the legs) -- called 'carotid-femoral pulse wave velocity'. A higher value indicates more stiffness and ageing of blood vessels. Measurements were taken six months after a COVID-19 infection and again after 12 months. An increase in pulse wave velocity of around 0.5 metres per second is clinically relevant and roughly amounts to ageing by five years, with a three per cent increased risk of cardiovascular disease, in a 60-year-old woman, the researchers said. The study found that, on average, pulse wave velocity among women who had a mild infection was increased by 0.55 metres per second, by 0.60 metres per second in those hospitalised and by over one metre per second for women treated in intensive care. "(Pulse wave velocity) differences were significant in women, but not in men. Among COVID-19 positive women, persistent symptoms were associated with higher (pulse wave velocity)," the authors wrote. "A stable or improved (pulse wave velocity) after 12 months was found in COVID-positive groups, whereas a progression was observed in the COVID-negative group," they wrote. Explaining how COVID-19 impacts blood vessels, Bruno said that the disease-causing virus "acts on specific receptors in the body, called the angiotensin-converting enzyme 2 receptors, that are present on the lining of the blood vessels." "The virus uses these receptors to enter and infect cells. This may result in vascular dysfunction and accelerated vascular ageing. Our body's inflammation and immune responses, which defend against infections, may also be involved," the lead researcher said. Further, compared to men, women are known to produce a more rapid and robust immune response which can protect from infection but can also inflict damage on blood vessels after initial infection, Bruno said. In a related editorial, published in the European Heart Journal, researchers from Harvard Medical School in the US wrote, "Although the acute threat of the COVID-19 (coronavirus disease 2019) pandemic has waned, a new challenge emerged in its aftermath: post-acute COVID-19 syndrome." The study highlights that "COVID-19's vascular legacy is real, measurable, and with a plausible likelihood of sex-specific findings," they wrote. "COVID-19 has aged our arteries, especially for female adults. The question is whether we can find modifiable targets to prevent this in future surges of infection, and mitigate adverse outcomes in those afflicted with COVID-19-induced vascular ageing," the authors said.>
The Hindu
5 hours ago
- The Hindu
How technology can help ease dementia diagnosis and care burden in India
Dementia is a growing problem, particularly in a country like India, which has a rapidly ageing population. Awareness, diagnosis and access to care however, continue to remain limited. Can digital and assistive technologies help? Researchers and doctors say there is a lot of potential, but the challenge is, in making them affordable for patients. The burden According to the World Health Organization (WHO), over 55 million people worldwide live with dementia, with nearly 10 million new cases added annually. Alzheimer's disease is the most common form, contributing to 60–70% of cases. Low- and middle-income countries, including India, bear the greatest burden, with dementia prevalence expected to triple by 2050 due to demographic ageing. Emerging technologies 'In India, assistive and digital technologies are emerging as force multipliers,' said Prabash Prabhakaran, director and senior consultant, neurology, SIMS Hospital, Chennai. These range from GPS trackers and low-cost Internet of Things (IoT) wearables for patients who wander or leave their designated areas, to home sensors that monitor movement, appliance usage, or medication adherence. Smartwatches and wearable devices for activity, sleep and fall detection are becoming more common, while smartphone-based cognitive screening apps and gamified brain-training tools are in validation stages. Virtual reality modules are also being piloted, designed in vernacular languages and Indian cultural settings for reminiscence therapy and navigation training. At the research frontier, Indian centres are developing blood-based biomarker panels for early Alzheimer's detection, alongside AI-driven multimodal digital biomarkers that combine gait, speech, typing patterns and passive smartphone signals. 'Earlier and scalable detection is becoming possible because smartphone penetration is high, even among older households,' Dr. Prabhakaran explained. Studies have shown that keystroke dynamics, speech analysis and passive phone use can serve as unobtrusive early-warning signals. Sindhuja L., consultant neurophysician at V.S. Hospitals, Chennai, said AI now picks up subtle changes 'in brain scans, speech or even handwriting that escape the human eye.' She noted that digital biomarkers such as walking speed and reaction time are being captured on tablets and smartphones, even by mobile health units visiting rural communities. Dr. Prabhakaran stressed that these technologies are not replacements for clinical diagnosis, but 'powerful early detection and monitoring tools, especially valuable in India where clinic-based testing is episodic.' Easing caregiver stress 'Dementia disrupts daily living, independence, and safety while burdening caregivers. Assistive technologies help maintain independence and reduce stress,' Dr. Prabhakaran said. In practice, families are using GPS trackers, pill-box alarms, fall detectors, and voice-assisted reminders. Smart-home solutions, such as motion-triggered lights and automatic stove shut-offs, are now feasible in urban settings. Therapeutic tools also show promise. Virtual reality reminiscence therapy has allowed patients to revisit festivals or familiar neighbourhoods, sparking positive memories. 'When families join in brain-training games in local languages, they turn into a shared, engaging activity instead of a medical routine,' Dr. Sindhuja said. Gaps and digital-first solutions Nearly two-thirds of India's older adults live in rural areas, where dementia specialists are scarce. 'Travel distance, cost, stigma, and shortage of trained specialists mean many cases remain undiagnosed or untreated,' Dr. Prabhakaran said. Here, telemedicine, remote monitoring, and community-driven digital platforms offer a bridge. Accredited frontline health workers can use smartphone screening apps, while caregivers rely on WhatsApp-based peer groups for emotional and practical support. Dr. Sindhuja emphasised that 'scheduled video calls or remote monitoring can catch problems before they escalate, making care less isolating.' High costs, lack of insurance, and uneven after-sales support remain critical hurdles. 'Most advanced devices are imported and unaffordable for average families,' said Dr. Sindhuja. In rural areas, poor connectivity worsens access. Cultural barriers also persist, as memory loss is still seen as part of normal ageing, leading to delayed care-seeking. Considering these challenges, Sridhar Vaitheeswaran, consultant psychiatrist and the head of DEMCARES (Dementia Care in SCARF) at the Schizophrenia Research Foundation (SCARF) in Chennai, said the Foundation, in collaboration with Imperial College London, has been working on technologies like the humanoid robot to assist people living with dementia, offering companionship and cognitive support. SCARF is also developing virtual reality services and using platforms such as Zoom to help patients connect with their families. The aim is to improve these tools and create more seamless ways for people with dementia to stay engaged and supported. Need for subsidies Dr. Prabhakaran called for policy interventions including subsidies, insurance inclusion, and local-language adaptation. He proposed 'digital dementia corners' at primary health centres, equipped with tablets, VR stations, and screening kiosks. Doctors emphasised the need for public–private partnerships to localise production, ensure affordability, and drive awareness campaigns in regional languages. Towards a national dementia-tech ecosystem A wide range of assistive technologies is used globally-- In Japan, scannable QR codes and wearable barcodes are widely used to help locate individuals who wander. The U.K. promotes the use of reminder clocks, smart home sensors and medication dispensers through the National Health Services and dementia charities. In the U.S., devices like AngelSense integrate GPS tracking, two-way communication and fall detection, offering comprehensive monitoring. Australia supports telecare systems and simplified tablets for memory and social engagement. Sweden and the Netherlands are pioneers in using smart homes and robotic companions for dementia care, incorporating AI and ambient monitoring. These innovations, however, remain out of reach for most Indian families. The challenge, experts argue, is not just scientific but systemic, ensuring that validated, affordable, culturally relevant technologies reach homes across India. The path forward lies in scalable, inclusive technology, integrated with grassroots healthcare and caregiver networks. As Dr. Prabhakaran explained, 'Assistive devices, GPS trackers, smart-home solutions, and therapeutic tools are not luxuries: they are critical enablers of safer, more independent living. With proper validation, affordability, and integration into national elder-care programmes, these technologies can transform dementia care in the coming decade.'
The Hindu
6 hours ago
- The Hindu
Don't panic over heart attacks as numbers show no alarming rise: Karnataka Minister
Asking the public not to panic over heart attacks, Medical Education Minister Sharan Prakash Patil on Monday said that the data does not show any significant increase. 'Lifestyle changes can prevent heart attack episodes. Though concerns have been raised over heart attacks, there has been no significant increase. On an average, 5% to 6% of the cases are heart-related. The trend remains the same this year too,' the Minister told Legislative Council in response to a question from Congress member Dinesh Gooligowda. 'Isolated incidents should not create panic among public.' The Minister also clarified that lifestyle has been major contributor to heart attacks. Dr. Patil said that there has been no evidence to link post-COVID-19 effects to heart attack cases, and a committee, led by K.S. Rabindranath, director of Sri Jayadeva Institute of Cardiovascular Sciences, and a task force set up by the Health department have dismissed any link between the two. Tele ECG to be expanded Meanwhile, to a question from BJP member Dhananjaya Sarji, Health and Family Welfare Minister Dinesh Gundu Rao said that the tele ECG facility will be extended to all taluk hospitals and PHCs across the State. Currently, it is available in 86 hospitals. He told the House that there is a proposal to install AED devices used to revive persons who suffer a heart attack at public places, including airports, bus stands and railway stations. Mr. Rao said that cathlabs have been proposed in Mangaluru, Hosapete, and at C.V. Raman Nagar in Bengaluru. Number of cases The Minister also informed the House that since heart attack was not a notifiable disease earlier, it was difficult to ascertain the exact number of cases. However, under Puneeth Rajkumar Hrudaya Jyothi scheme, 1,004 heart attack-related deaths were reported in the last three years at primary care centres. At Sri Jayadeva Institute, 6.12 lakh heart-attack cases have been reported in which 472 persons below 45 years have died. He further stated that the Dr. Rabindranath committee has found that in nearly 75% of all cases persons were at risk owing to more than one factor.
